GE HealthCare Technologies Inc. (NASDAQ:GEHC) is reportedly discussing a possible $1 billion acquisition of Sofie Biosciences. Reuters reported the talks on September 13, citing the Financial Times, which attributed them to people familiar with the matter. Reuters could not independently verify the report, and no agreement was confirmed in its coverage.
The strategic question starts with an existing relationship. Under an October 2023 agreement, GE HealthCare Technologies Inc. licensed global rights to Gallium-68 FAPI-46 and rights outside the United States to Fluorine-18 FAPI-74. Sofie retained U.S. clinical-development and commercialization rights to F-18 FAPI-74.
These investigational radiotracers target fibroblast activation protein, or FAP, for positron emission tomography scans. For GE HealthCare Technologies Inc., ownership would need to deliver enough additional rights, manufacturing earnings, and operational benefits to justify the reported price.
Bull Case
The retained U.S. rights present a concrete potential addition. If included in a transaction, they would expand the geographic scope of GE HealthCare Technologies Inc.’s F-18 FAPI-74 interests beyond the published licensing package. That could align development and commercialization decisions across markets.
Sofie also brings an operating manufacturing base. In January, Sofie said seven radiopharmacies were producing F-18 FAPI-74. GE HealthCare Technologies Inc. could gain greater control over production capacity, supply planning and the economics of manufacturing services. Those capabilities extend beyond access to intellectual property.
The development program has advanced since the original licensing announcement. In February, Sofie announced the first patient dosed in its Phase 3 pancreatic-cancer imaging study, alongside a gastroesophageal-cancer study that had dosed its first patient in December 2025.
For GE HealthCare Technologies Inc., combining retained rights, development assets and manufacturing operations could strengthen its pharmaceutical diagnostics business. Existing collaboration also provides experience working with the target, potentially helping integration planning.
Bear Case
GE HealthCare Technologies Inc. already holds substantial licensed rights. Investors should therefore assess the value added by ownership against the alternative of continuing the commercial relationship. Growth already accessible under existing licenses should not be counted again as a new acquisition benefit.
The reported $1 billion figure provides no earnings multiple. Reuters’ report did not disclose Sofie’s revenue, operating profit, cash generation, or financing terms. Without those details, the price cannot be assessed against sustainable returns or the cost of funding the purchase.
Manufacturing ownership would also bring obligations for GE HealthCare Technologies Inc.. Facility investment, quality controls, staffing, and integration spending could absorb part of any additional earnings. Production capacity becomes more valuable when demand supports utilization and pricing.
Clinical development remains another hurdle. Entering Phase 3 establishes progress, while diagnostic performance, regulatory review, and eventual adoption determine commercial potential. GE HealthCare Technologies Inc. would need to evaluate remaining development costs alongside the purchase price. Licensing relationships can provide access to innovation without requiring ownership of the entire operating business.
Hedge Fund Sentiment
The filings available so far reflect positions held before the September 13 report concerning GE HealthCare Technologies Inc. and Sofie Biosciences. Insider Monkey’s database showed 59 hedge funds holding GE HealthCare Technologies Inc. at the end of 2Q2026, down from 60 funds three months earlier.
Conclusion
GE HealthCare Technologies Inc. has a plausible strategic reason to consider ownership: retained U.S. rights and manufacturing operations could add to its existing licenses. The investment case depends on the exact assets included, target financials, and returns after development and integration spending. A confirmed agreement would make those questions concrete; reported talks alone leave the valuation unresolved.
READ NEXT: CBRE Group (CBRE) Unit Buys $1.6 Billion Net-Lease Platform. Can Scale Lift Fee Earnings? and Mastercard (MA) Partners With Flowcart. Can In-Chat Payments Deliver Profitable Growth?
This article is originally published at Insider Monkey.
